Circulating Tumor Cells in Solid Tumors
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03161821 |
Recruitment Status :
Suspended
(New enrollment and collection of blood samples paused while IRB reviews use of the investigational assay involved.)
First Posted : May 22, 2017
Last Update Posted : December 24, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Solid Tumor, Adult | Other: Observational |
Study Type : | Observational |
Estimated Enrollment : | 500 participants |
Observational Model: | Other |
Time Perspective: | Prospective |
Official Title: | Quantification and Characterization of Circulating Tumor Cells in Solid Tumors |
Actual Study Start Date : | December 9, 2011 |
Estimated Primary Completion Date : | December 1, 2022 |
Estimated Study Completion Date : | December 1, 2022 |
- Documentation of the Quality of CTCs from Patients with Solid Tumors [ Time Frame: Through study completion, an average of 5 years ]Enumeration of participants' circulating solid tumor cells
- Documentation of the Characterization of CTCs from Patients with Solid Tumors [ Time Frame: Through study completion, an average of 5 years ]Characterization of participants' circulating solid tumor cells

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Age ≥ 18 years of age
- Biopsy proven solid tumor malignancy
- Seen at UNC Chapel Hill Hospital and Health Care System
- Consents to abstraction of their medical records
- Signed an institutional review board (IRB)-approved informed consent document for this protocol
Exclusion Criteria:
- < 18 years of age
- Dementia, altered mental status, incarceration or any psychiatric condition that would prohibit the understanding or rendering of informed consent.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03161821
United States, North Carolina | |
Radiation Oncology Clinic - UNC Cancer Hospital | |
Chapel Hill, North Carolina, United States, 27599 |
Principal Investigator: | Gaorav P Gupta, MD, MPH | University of North Carolina |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | UNC Lineberger Comprehensive Cancer Center |
ClinicalTrials.gov Identifier: | NCT03161821 |
Other Study ID Numbers: |
LCCC 1121 11-1924 ( Other Identifier: UNC IRB ) |
First Posted: | May 22, 2017 Key Record Dates |
Last Update Posted: | December 24, 2020 |
Last Verified: | December 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Neoplastic Cells, Circulating Neoplasms Neoplasm Metastasis Neoplastic Processes Pathologic Processes |